SCHEMBL3098496

SCHEMBL3098496

COc1ccc2oc(C(=O)N3CC(O)C(N4CCN(Cc5ccc(Cl)cc5)CC4)C3)cc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 1/20 0.44
▸ DRD2 P14416 2/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ DPP4 P27487 1/20 0.42
▸ DPP8 Q6V1X1 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ SLC18A3 Q16572 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ WNK1 Q9H4A3 1/20 0.41
▸ GRIN2B Q13224 1/20 0.41
▸ IDO1 P14902 1/20 0.41
▸ MAOA P21397 1/20 0.41
▸ HTR1A P08908 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13158054 1.00 HRH4 (0.44) HRH4DRD2DRD3NPC1RAB9A
SCHEMBL3108214 0.90 RAB9A (0.54) HRH4NPC1RAB9ADPP4DPP8
SCHEMBL13158059 0.90 RAB9A (0.54) HRH4NPC1RAB9ADPP4DPP8
SCHEMBL3093260 0.86 GRIN2B (0.57) HRH4DRD2DRD3NPC1RAB9A
SCHEMBL13157902 0.86 GRIN2B (0.57) HRH4DRD2DRD3NPC1RAB9A
SCHEMBL3100172 0.82 KDM4E (0.45) DRD2DRD3DPP4ALDH1A1KDM4E
SCHEMBL13158074 0.82 KDM4E (0.45) DRD2DRD3DPP4ALDH1A1KDM4E
SCHEMBL3092446 0.78 HRH4 (0.58) HRH4NPC1RAB9ADPP4DPP8
SCHEMBL13158090 0.78 HRH4 (0.58) HRH4NPC1RAB9ADPP4DPP8
SCHEMBL11343183 0.77 GRIN2B (0.66) DRD2DRD3ALDH1A1KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399455-B2 Compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-03-19 — — US disclosed
US-20100234356-A1 COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-09-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234356-A1 COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS ACKR3, CCR5, CXCR2 HRH4 448/4885DRD2 3087/4885DRD3 3574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback